분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-06-23 19:02:48 , Hit : 1133
 A single gene turns colorectal cancer cells back into normal tissue in mice


Public Release: 18-Jun-2015
Cell Press



Credit: Kevin P. O'Rourke


Anti-cancer strategies generally involve killing off tumor cells. However, cancer cells may instead be coaxed to turn back into normal tissue simply by reactivating a single gene, according to a study published June 18th in the journal Cell. Researchers found that restoring normal levels of a human colorectal cancer gene in mice stopped tumor growth and re-established normal intestinal function within only 4 days. Remarkably, tumors were eliminated within 2 weeks, and signs of cancer were prevented months later. The findings provide proof of principle that restoring the function of a single tumor suppressor gene can cause tumor regression and suggest future avenues for developing effective cancer treatments.

Colorectal cancer is the second leading cause of cancer-related death in developed countries, accounting for nearly 700,000 deaths worldwide each year. "Treatment regimes for advanced colorectal cancer involve combination chemotherapies that are toxic and largely ineffective, yet have remained the backbone of therapy over the last decade," says senior study author Scott Lowe of the Memorial Sloan Kettering Cancer Center.

Up to 90% of colorectal tumors contain inactivating mutations in a tumor suppressor gene called adenomatous polyposis coli (Apc). Although these mutations are thought to initiate colorectal cancer, it has not been clear whether Apc inactivation also plays a role in tumor growth and survival once cancer has already developed.

"We wanted to know whether correcting the disruption of Apc in established cancers would be enough to stop tumor growth and induce regression," says first author Lukas Dow of Weill Cornell Medical College. This question has been challenging to address experimentally because attempts to restore function to lost or mutated genes in cancer cells often trigger excess gene activity, causing other problems in normal cells.

To overcome this challenge, Lowe and his team used a genetic technique to precisely and reversibly disrupt Apc activity in a novel mouse model of colorectal cancer. While the vast majority of existing animal models of colorectal cancer develop tumors primarily in the small intestine, the new animal model also developed tumors in the colon, similar to patients. Consistent with previous findings, Apc suppression in the animals activated the Wnt signaling pathway, which is known to control cell proliferation, migration, and survival.

When Apc was reactivated, Wnt signaling returned to normal levels, tumor cells stopped proliferating, and intestinal cells recovered normal function. Tumors regressed and disappeared or reintegrated into normal tissue within 2 weeks, and there were no signs of cancer relapse over a 6-month follow-up period. Moreover, this approach was effective in treating mice with malignant colorectal cancer tumors containing Kras and p53 mutations, which are found in about half of colorectal tumors in humans.

Although Apc reactivation is unlikely to be relevant to other types of cancer, the general experimental approach could have broad implications. "The concept of identifying tumor-specific driving mutations is a major focus of many laboratories around the world," Dow says. "If we can define which types of mutations and changes are the critical events driving tumor growth, we will be better equipped to identify the most appropriate treatments for individual cancers."

For their own part, Lowe and his team will next examine the consequences of Apc reactivation in tumors that progress beyond local invasion to produce distant metastases. They will also continue to investigate why Apc is so effective at suppressing colon tumor growth, with the goal of one day mimicking this effect with drug treatments.

"It is currently impractical to directly restore Apc function in patients with colorectal cancer, and past evidence suggests that completely blocking Wnt signaling would likely be severely toxic to normal intestinal cells," Lowe says. "However, our findings suggest that small molecules aimed at modulating, but not blocking, the Wnt pathway might achieve similar effects to Apc reactivation. Further work will be critical to determine whether WNT inhibition or similar approaches would provide long-term therapeutic value in the clinic."


Cell, Dow et al.: "Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer."

http://dx.​doi.​org/​10.​1016/​j.​cell.​2015.​05.​033







1127   항체를 이용한 HIV치료법  이성욱 2015/04/15 1110
1126   HIV에 방어하는 박테리아가 인체에 존재한다?  이성욱 2015/10/12 1112
1125   영국 의회, `세 부모 아기` 합법화  이성욱 2015/02/06 1113
1124   iPS세포 '미니 간' 대량생산장치 개발  이성욱 2015/02/23 1113
1123   C형 간염에 보다 효과적인 새로운 복합제  이성욱 2015/11/24 1118
1122   한국의 MERS가 글로벌 보건을 위협할 수 있을까?  이성욱 2015/06/09 1126
1121   유전자 조작인간배아를 만들어낸 중국과학자들  이성욱 2015/04/27 1131
1120   DNA 앰블런스  이성욱 2015/07/30 1131
1119   세균의 도구로 식물 DNA 편집  이성욱 2015/06/09 1132
  A single gene turns colorectal cancer cells back into normal tissue in mice  이성욱 2015/06/23 1133
1117   Off Switch Found for Common Version of the CRISPR-Cas9 System  이성욱 2017/01/02 1134
1116   2018 Lasker Award Winners: Gene Expression Researchers, Propofol Discoverer, Pioneer for RNA Biology, and Women in STEM  이성욱 2018/09/12 1134
1115   Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1136
1114   인간배아 DNA편집을 둘러싼 논란  이성욱 2015/03/17 1136
1113   세부모 배아의 대안적 방법  이성욱 2015/04/29 1137
1112   Beyond CRISPR Cuts: Five Complements To Cas9  이성욱 2017/02/24 1137
1111   Drug flushes out hidden AIDS virus  이성욱 2015/03/07 1140
1110   유전자 가위, 매머드 복원-안전한 백신의 시대 리본 자르다  이성욱 2016/03/14 1140
1109   화성의 물에서 생명체를 찾는 것의 어려움  이성욱 2015/10/01 1150
1108   Fixing CRISPR  이성욱 2017/06/27 1150

[1][2][3][4][5][6][7] 8 [9][10]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN